We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+10.97%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.05B
AUM Growth
+$206M
Cap. Flow
-$221M
Cap. Flow %
-4.38%
Top 10 Hldgs %
83.23%
Holding
98
New
29
Increased
15
Reduced
26
Closed
6

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$8.14M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$7.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$6.05M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$4.89M
5
NTB icon
Bank of N.T. Butterfield & Son
NTB
+$4.86M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$699M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.1M
3
C icon
Citigroup
C
+$10.6M
4
BABA icon
Alibaba
BABA
+$9.27M
5
APTV icon
Aptiv
APTV
+$8.43M

Sector Composition

Rank Sector Weight
1 Consumer Staples 41.33%
2 Healthcare 27.87%
3 Consumer Discretionary 7.22%
4 Financials 1.42%
5 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
51
DELISTED
Juno Therapeutics, Inc.
JUNO
$6M 0.12%
200,000
– –
RXDX
52
DELISTED
Ignyta, Inc.
RXDX
$5.35M 0.11%
850,000
+100,000
+13% +$581K
USFD icon
53
US Foods
USFD
$22.5B
$5.31M 0.11%
225,000
-275,000
-55% -$6.67M
NBIX icon
54
Neurocrine Biosciences
NBIX
$18.2B
$5.06M 0.1%
100,000
+5,000
+5% +$249K
SPNC
55
DELISTED
Spectranetics Corp
SPNC
$5.02M 0.1%
200,000
-150,000
-43% -$3.5M
LCTX icon
56
Lineage Cell Therapeutics
LCTX
$264M
$5M 0.1%
1,465,383
– –
NTB icon
57
Bank of N.T. Butterfield & Son
NTB
$2.41B
$4.95M 0.1%
+200,000
New +$4.86M
CEMP
58
DELISTED
Cempra, Inc.
CEMP
$4.84M 0.1%
200,000
+100,000
+100% +$2.15M
ATRA icon
59
Atara Biotherapeutics
ATRA
$72.6M
$4.81M 0.1%
+9,000
New +$4.89M
FOLD
60
CALL
DELISTED
Amicus Therapeutics
FOLD
$4.81M 0.1%
+650,000
New +$4.39M
TCOM icon
61
Trip.com Group
TCOM
$29B
$4.66M 0.09%
+100,000
New +$4.45M
MGNX icon
62
MacroGenics
MGNX
$233M
$4.49M 0.09%
+150,000
New +$4.46M
ELF icon
63
e.l.f. Beauty
ELF
$4.77B
$4.22M 0.08%
+150,000
New +$3.93M
RGNX icon
64
Regenxbio
RGNX
$616M
$4.2M 0.08%
300,000
+100,000
+50% +$1.1M
CLLS
65
Cellectis
CLLS
$288M
$3.61M 0.07%
150,000
-60,000
-29% -$1.57M
AGEN
66
CALL
Agenus
AGEN
$276M
$3.59M 0.07%
25,475
– –
RARE icon
67
CALL
Ultragenyx Pharmaceutical
RARE
$2.46B
$3.55M 0.07%
+50,000
New +$3.19M
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$2.46B
$3.55M 0.07%
50,000
-25,000
-33% -$1.6M
VVV icon
69
Valvoline
VVV
$5.06B
$3.52M 0.07%
+150,000
New +$3.54M
SIOX
70
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.5M 0.07%
+31,250
New +$3.75M
NTLA icon
71
Intellia Therapeutics
NTLA
$1.51B
$3.49M 0.07%
205,000
-20,000
-9% -$387K
IRWD icon
72
Ironwood Pharmaceuticals
IRWD
$586M
$3.44M 0.07%
258,954
– –
BLUE
73
CALL
DELISTED
bluebird bio
BLUE
$3.39M 0.07%
3,860
-3,860
-50% -$2.8M
ONCE
74
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$3M 0.06%
50,000
– –
JUNO
75
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$3M 0.06%
100,000
+50,000
+100% +$1.56M
1 2
3
4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2016 Portfolio in Review

As of Q3 2016, Artal Group held 98 positions worth $5.05B, up 4.3% from $4.84B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $221M in Q3 2016, closing 6 positions and reducing 26 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $20.1M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 41% of assets, down from 56% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Sage Therapeutics worth $9.21M.

  • Artal Group's largest Q3 2016 buy was Sage Therapeutics: 200,000 shares worth $9.21M.
  • Artal Group added most to Amicus Therapeutics in Q3 2016, an estimated $4.39M increase.
  • Artal Group's biggest Q3 2016 reduction was Blue Buffalo Pet Products, Inc, cutting an estimated $699M.
  • Artal Group fully exited Regeneron Pharmaceuticals in Q3 2016, selling an estimated $20.1M.
  • Artal Group's ten largest holdings make up 83% of its $5.05B portfolio in Q3 2016.
  • Artal Group opened 29 new positions and closed 6 in Q3 2016.
  • Artal Group's portfolio value rose 4.3% quarter-over-quarter to $5.05B.

Based on Artal Group's 13F filing for Q3 2016, filed 14 Nov 2016.